ÂÜÀòÂÒÂ×

Martin Heidecker, Ph.D. is Chief Investment Officer of the AMR Action Fund. He joined the AMR Action Fund in August 2021 coming from Boehringer Ingelheim Venture Fund where he worked as Managing Director USA in Cambridge, MA. He served as a board director of ArmaGen Technologies, Inc (acquired by JCR Pharma), Tilos Therapeutics Inc. (acquired by Merck & Co Inc.), Sentien Biotechnologies Inc., Abexxa Biologics Inc., Libra Therapeutics Inc., and Rgenta Therapeutics Inc. Dr. Heidecker also serves on the Board of Directors of MassBio. He started his career at BayernKapital in the early 2000s to focus on seed investments in biotechnology companies in Germany. He held several Marketing positions at Solvay Pharmaceuticals and Boehringer Ingelheim in CNS and Oncology and was involved in the launch of various drugs in the CNS space. Dr. Heidecker holds a Ph.D. in Biology from the University of Würzburg and an MBA from FernUniversität Hagen.